FIELD: medicine.
SUBSTANCE: invention refers to pharmaceutics. A method involves internal introduction of an effective amount of N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide into a human. Major depression involves at least one symptom selected from a group consisting of: permanent sadness, anxiety or indifference; a feeling of despair; pessimism; a feeling of remorse, uselessness or helplessness; loss of interest or pleasure of passions and actions previously delighted, including sex; lower power, fatigue or inhibited existence; concentration, memory or decision-making problems; insomnia, very early awakening or oversleeping; loss of appetite and/or weight or overeating and weight gain; death and suicide thoughts; attempted suicides; restlessness; impatience; persistent unresponsive physical symptoms including headache, dyspepsia and chronic pain, and any combination thereof.
EFFECT: method provides effective prevention and treatment of major depression symptoms.
2 cl, 2 tbl, 3 ex
